Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
Go back to Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
June 20, 2024 6:10 AM EDT
UBS analyst Eliana Merle downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Buy to Neutral with a price target of $5.00 (from $28.00).
The analyst comments "We think WEE1 has potential in ovarian and USC, but we see uncertainty and have limited visibility on next steps given partial clinical hold announced 6/18 A partial clinical hold was placed by the FDA on azenosertib (WEE1... More
June 18, 2024 2:19 PM EDT
Jefferies analyst Akash Tewari downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Buy to Hold with a price target of $6.00 (from $42.00).
The analyst comments "ZNTL announced the FDA placed a partial clinical hold on 3 mono azenosertib studies after 2 deaths presumably due to sepsis (neutropenia &... More
June 18, 2024 1:32 PM EDT
Morgan Stanley analyst Matthew Harrison downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Overweight to Equalweight with a price target of $8.00 (from $38.00).
The analyst comments "Lead program azenosertib placed on partial clinical hold by the FDA due to safety concerns. While we continue to believe... More
June 18, 2024 12:13 PM EDT
H.C. Wainwright analyst Andrew Fein lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $20.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "Azenosertibs clinical hold is based on toxicity issues well known to WEE1i. This morning, Zentalis announced that the FDA has placed three clinical studies of azenosertib (ZN-c3-001, ZN-c3-004/TETON, and ZN-c3-005/DENALI) on partial hold following two drug-related Grade 5 events... More
